Director, International Drug Information Center

Articles

Five medications are currently approved by the FDA for chronic weight management.

A Review of FDA-Approved Medications for Chronic Weight Management

Sol-Gel Technologies has created a single-application acne treatment cream, combining 2 commonly used ingredients: tretinoin and benzoyl peroxide.





Fixed-Dose Combo Cream Treatment Approved for Acne Vulgaris

Ms. Hester is Content Specialist with Contemporary OB/GYN and Contemporary Pediatrics.

The FDA has approved the AstraZeneca once-weekly injectable therapy for use in children aged 10 to 17 years.

FDA OKs Treatment for Adolescents With Type 2 Diabetes

Kathryn Wheeler, PharmD, BCPS, is assistant clinical professor of pharmacy practice, University of Connecticut School of Pharmacy, Storrs, Conn.

On June 2,2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the FDA for vulvovaginal candidiasis (VVC) in adult women and girls who have begun menstruating.




Novel Antifungal Treatment Approved for Vaginal Candidiasis    

Jennifer Barrett is the senior editor for 

The FDA has approved OTC azelastine HCl .15% (Astepro Allergy; Bayer).

FDA OKs OTC Use of Steroid-Free Antihistamine Allergy Nasal Spray

The vaccine is indicated to prevent invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes.

FDA Approves Pneumococcal 20-Valent Conjugate Vaccine for Adults

The FDA approved Cosentyx (secukinumab) to treat moderate-to-severe plaque psoriasis in children aged 6 years and older.

FDA OKs Secukinumab for Children Aged 6 and Older

In a session from the PDS 2021 Virtual Super-Conference, experts discussed how POC testing capabilities enhance patient services and address antimicrobial resistance.

Boost Revenue and Patient Satisfaction With Point-of-Care Testing

Kendall Szulimowski is a 2021 PharmD candidate at the University of Connecticut School of Pharmacy in Storrs.

Samantha Troy is a 2021 PharmD candidate at the University of Connecticut School of Pharmacy in Storrs.

Associate Clinical Professor, University of Connecticut School of Pharmacy, Storrs, CT.

Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma. 

Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

This indication is approved under accelerated approval based on tumor response rate and durability of response.

New Products